JP5518488B2 - 巨大分子伝達ドメインならびにその同定方法および使用 - Google Patents

巨大分子伝達ドメインならびにその同定方法および使用 Download PDF

Info

Publication number
JP5518488B2
JP5518488B2 JP2009547177A JP2009547177A JP5518488B2 JP 5518488 B2 JP5518488 B2 JP 5518488B2 JP 2009547177 A JP2009547177 A JP 2009547177A JP 2009547177 A JP2009547177 A JP 2009547177A JP 5518488 B2 JP5518488 B2 JP 5518488B2
Authority
JP
Japan
Prior art keywords
peptide
protein
mtd
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009547177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516758A (ja
JP2010516758A5 (enExample
Inventor
デ ウン ジョ
ゼ ソン コ
ジン スク キム
キョン ミ パク
ジン キョン ソン
ジョン ヒ イム
チ チュイ ガ ド
チ ラン フォング ド
ミン タム ドング
Original Assignee
プロセル セラピューティックス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロセル セラピューティックス インコーポレーティッド filed Critical プロセル セラピューティックス インコーポレーティッド
Publication of JP2010516758A publication Critical patent/JP2010516758A/ja
Publication of JP2010516758A5 publication Critical patent/JP2010516758A5/ja
Application granted granted Critical
Publication of JP5518488B2 publication Critical patent/JP5518488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009547177A 2007-01-29 2008-01-29 巨大分子伝達ドメインならびにその同定方法および使用 Active JP5518488B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88706007P 2007-01-29 2007-01-29
US60/887,060 2007-01-29
PCT/KR2008/000525 WO2008093982A1 (en) 2007-01-29 2008-01-29 Novel macromolecule transduction domains and methods for identification and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013207349A Division JP2014057586A (ja) 2007-01-29 2013-10-02 巨大分子伝達ドメインならびにその同定方法および使用

Publications (3)

Publication Number Publication Date
JP2010516758A JP2010516758A (ja) 2010-05-20
JP2010516758A5 JP2010516758A5 (enExample) 2011-04-21
JP5518488B2 true JP5518488B2 (ja) 2014-06-11

Family

ID=39674245

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009547177A Active JP5518488B2 (ja) 2007-01-29 2008-01-29 巨大分子伝達ドメインならびにその同定方法および使用
JP2013207349A Pending JP2014057586A (ja) 2007-01-29 2013-10-02 巨大分子伝達ドメインならびにその同定方法および使用
JP2015090144A Active JP6140759B2 (ja) 2007-01-29 2015-04-27 巨大分子伝達ドメインならびにその同定方法および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013207349A Pending JP2014057586A (ja) 2007-01-29 2013-10-02 巨大分子伝達ドメインならびにその同定方法および使用
JP2015090144A Active JP6140759B2 (ja) 2007-01-29 2015-04-27 巨大分子伝達ドメインならびにその同定方法および使用

Country Status (8)

Country Link
US (2) US8629097B2 (enExample)
EP (2) EP2129682A4 (enExample)
JP (3) JP5518488B2 (enExample)
KR (18) KR20090103957A (enExample)
CN (1) CN101616928B (enExample)
AU (1) AU2008211854C1 (enExample)
CA (1) CA2676797C (enExample)
WO (1) WO2008093982A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
KR20090122946A (ko) 2007-02-27 2009-12-01 주식회사 프로셀제약 줄기세포의 자가-재생을 촉진하고 분화를 억제하기 위한 세포투과성 ｎａｎｏｇ 및 ｏｃｔ４의 병합 용도
KR100887266B1 (ko) * 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
JP5295242B2 (ja) * 2007-09-04 2013-09-18 プロセル セラピューティックス インコーポレーティッド 細胞透過性Ｎｍ２３組換えタンパク質、これをコードするポリヌクレオチド及びこれを有効成分として含有する癌転移抑制用組成物
EP2209892A2 (en) * 2007-11-06 2010-07-28 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
EP2270055A4 (en) * 2008-04-04 2011-06-29 Procell Therapeutics Inc CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE
US20120095188A1 (en) * 2009-03-12 2012-04-19 Procell Therapeutics Inc. Establishment of induced pluripotent stem cell using cell-permeable reprogramming transcription factor for customized stem cell therapy
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
TW201302800A (zh) * 2011-06-10 2013-01-16 Oncotherapy Science Inc Ｓｅｍａ５ｂ胜肽及含其之疫苗
US8859507B2 (en) 2011-08-16 2014-10-14 Samsung Electronics Co., Ltd. Protein complex for intracellular delivery and uses thereof
KR101258279B1 (ko) * 2011-11-23 2013-04-25 주식회사 프로셀제약 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
WO2013077681A1 (ko) * 2011-11-23 2013-05-30 주식회사 프로셀제약 세포내 분자 전송 펩티드를 이용한 피부 생리 활성 분자의 경피 전달시스템
US9259481B2 (en) 2011-11-23 2016-02-16 Procell Therapeutics Inc. Development of novel macromolecule transduction domain with improved cell permeability and method for using same
ES3046661T3 (en) 2012-05-11 2025-12-02 Gemvax & Kael Co Ltd Anti-inflammatory peptides and composition comprising the same
KR101997756B1 (ko) 2012-05-11 2019-07-08 주식회사 젬백스앤카엘 패혈증 예방 또는 치료용 조성물
CA2877384C (en) * 2012-07-02 2023-05-09 Iprogen Biotech Inc. Intracellular protein delivery
KR101799904B1 (ko) 2012-07-11 2017-11-22 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP2899201B1 (en) 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
ES2743919T3 (es) 2012-09-19 2020-02-21 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
EP4063863A1 (en) 2013-06-07 2022-09-28 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
GB201315321D0 (en) 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
CN105899224B (zh) 2013-10-23 2019-12-13 珍白斯凯尔有限公司 用于治疗和预防良性前列腺增生的组合物
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015093854A1 (ko) 2013-12-17 2015-06-25 주식회사 카엘젬백스 전립선 암 치료용 조성물
US10137079B2 (en) 2014-02-20 2018-11-27 Cura Health Inc. Transdermal composition for treating pain
KR102373603B1 (ko) 2014-04-11 2022-03-14 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
CN106459155B (zh) 2014-05-29 2019-10-25 株式会社普罗赛尔制药 新颖细胞穿透肽、其与肉毒杆菌毒素的缀合物以及其用途
US10323063B2 (en) 2014-08-17 2019-06-18 Cellivery Therapeutics, Inc. Advanced macromolecule transduction domain (aMTD) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of aMTDs comprising the same, method to develop the aMTD sequences comprising the same
US20160060310A1 (en) * 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Hepatocellular Carcinoma Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Hepatocellular Carcinoma Compositions Comprising the Same
CN104548073B (zh) * 2014-12-12 2017-08-11 浙江大学 Prx I重组蛋白在制备抗细菌性败血症药物中的应用
EP3237434A1 (en) * 2014-12-22 2017-11-01 F. Hoffmann-La Roche AG Cell penetrating peptides
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
ES2799511T3 (es) 2015-02-27 2020-12-18 Gemvax & Kael Co Ltd Péptido para prevenir la pérdida de audición, y composición que lo comprende
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US20170029798A1 (en) * 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
EP3334755B1 (en) * 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
WO2017026779A1 (en) 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
EP3337815B1 (en) 2015-08-18 2020-12-16 Cellivery Therapeutics, Inc. Cell-permeable (cp)- socs3 recombinant protein and uses thereof
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
KR101800407B1 (ko) * 2016-04-04 2017-11-22 건국대학교 산학협력단 비단뱀으로부터 분리한 신규한 항균 펩타이드 및 이의 발굴 방법
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
AU2017341736B2 (en) * 2016-10-12 2022-09-08 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
US11517616B2 (en) 2016-10-23 2022-12-06 Denka Company Limited Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof
CN106995487B (zh) * 2017-04-17 2019-12-03 扬州大学 源于鸡传染性贫血病毒VP1-aa 23-43多肽作为高效细胞穿膜肽的应用
CN106831957B (zh) * 2017-04-17 2019-12-03 扬州大学 一种源于鸡传染性贫血病毒VP1-aa 1-19多肽作为高效细胞穿膜肽的应用
EP3719032A4 (en) 2017-12-01 2021-09-01 Good T Cells, Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1031959C (zh) * 1991-04-11 1996-06-05 住友电气工业株式会社 测量涂层状态的方法和设备
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO2002064057A2 (en) * 2001-02-15 2002-08-22 Baylor College Of Medicine Use of cell penetrating peptides to generate antitumor immunity
JP4188909B2 (ja) * 2002-03-29 2008-12-03 クレアゼン インコーポレーテッド 細胞質残留性細胞膜透過ペプチド及びこれの用途｛ＣｙｔｏｐｌａｓｍｉｃＴｒａｎｓｄｕｃｔｉｏｎＰｅｐｔｉｄｅｓａｎｄＵｓｅｓｔｈｅｒｅｏｆ｝
US6835810B2 (en) * 2002-05-13 2004-12-28 Geneshuttle Biopharma, Inc. Fusion protein for use as vector
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20070154437A1 (en) * 2002-09-03 2007-07-05 Pingfan Rao Peptide-tagged proteins and methods of making and using thereof
US20040043463A1 (en) * 2002-09-03 2004-03-04 Pingfan Rao Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids

Also Published As

Publication number Publication date
KR102217308B1 (ko) 2021-02-18
KR20200028359A (ko) 2020-03-16
KR102217325B1 (ko) 2021-02-18
KR102217281B1 (ko) 2021-02-18
KR102217299B1 (ko) 2021-02-18
KR20200028364A (ko) 2020-03-16
JP2010516758A (ja) 2010-05-20
KR20200027935A (ko) 2020-03-13
JP2015146820A (ja) 2015-08-20
KR20200029405A (ko) 2020-03-18
CA2676797C (en) 2014-04-22
KR102217277B1 (ko) 2021-02-18
AU2008211854A1 (en) 2008-08-07
AU2008211854C1 (en) 2014-01-23
KR102217313B1 (ko) 2021-02-18
KR102217269B1 (ko) 2021-02-18
KR20200027934A (ko) 2020-03-13
KR20200028353A (ko) 2020-03-16
KR102217295B1 (ko) 2021-02-18
EP2129682A4 (en) 2011-07-20
EP2837636A2 (en) 2015-02-18
KR20200029404A (ko) 2020-03-18
KR20200028356A (ko) 2020-03-16
KR20200028357A (ko) 2020-03-16
CN101616928B (zh) 2015-04-15
AU2008211854B2 (en) 2012-08-16
EP2837636A3 (en) 2015-07-15
US8629097B2 (en) 2014-01-14
KR20200028361A (ko) 2020-03-16
KR102217321B1 (ko) 2021-02-18
KR20090103957A (ko) 2009-10-01
KR20200028362A (ko) 2020-03-16
KR102217274B1 (ko) 2021-02-18
KR102217324B1 (ko) 2021-02-18
KR20200028355A (ko) 2020-03-16
EP2129682A1 (en) 2009-12-09
KR102217331B1 (ko) 2021-02-18
US20100197598A1 (en) 2010-08-05
KR102217310B1 (ko) 2021-02-18
KR20160068704A (ko) 2016-06-15
CA2676797A1 (en) 2008-08-07
JP2014057586A (ja) 2014-04-03
EP2837636B1 (en) 2018-04-11
KR20200028354A (ko) 2020-03-16
KR102217317B1 (ko) 2021-02-18
US9040477B2 (en) 2015-05-26
KR20200028360A (ko) 2020-03-16
KR20200028363A (ko) 2020-03-16
KR102217304B1 (ko) 2021-02-18
US20140186379A1 (en) 2014-07-03
KR102254723B1 (ko) 2021-05-24
KR20200028358A (ko) 2020-03-16
CN101616928A (zh) 2009-12-30
KR102217320B1 (ko) 2021-02-18
WO2008093982A1 (en) 2008-08-07
JP6140759B2 (ja) 2017-05-31

Similar Documents

Publication Publication Date Title
JP5518488B2 (ja) 巨大分子伝達ドメインならびにその同定方法および使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120420

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131114

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140402

R150 Certificate of patent or registration of utility model

Ref document number: 5518488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250